Use of mesna to prevent ifosfamide-induced urotoxicity

Supportive Care in Cancer

Volumn 6, Issue 2, 1998, Pages 144-154

  Siu, Lillian L ^a   Moore, Malcolm J ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Dose; Ifosfamide; Mesna; Schedule; Urotoxicity

Indexed keywords

IFOSFAMIDE; MESNA;

ARTICLE; CANCER CHEMOTHERAPY; DRUG EFFICACY; DYSURIA; HEMATURIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALIGNANT NEOPLASTIC DISEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT OUTCOME; URINARY TRACT DISEASE;

ANTINEOPLASTIC AGENTS, ALKYLATING; DRUG ADMINISTRATION SCHEDULE; HUMANS; IFOSFAMIDE; KIDNEY; KIDNEY FAILURE; MESNA;

EID: 0031887269     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050149     Document Type: Article

References (75)

1. Dechant KL, Brogden RN, Pilkington T, et al (1991) Ifosfamide/mesna: a review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 42:428-467
2. Sarosy G (1989) Ifosfamide - pharmacologic overview. Semin Oncol 16 [Suppl 3]:2-8
3. Kaijser GP, Beijnen JH, Bult A, et al (1994) Ifosfamide metabolism and pharmacokinetics (review). Anticancer Res 14:517-532
4. Wagner T (1994) Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet 26:439-456
5. Goren MP (1992) Oral mesna: a review. Semin Oncol 6 [Suppl 12]:65-72
6. Stofer-Vogel B, Cerny T, Borner M, et al (1993) Oral bioavailability of mesna tablets. Cancer Chemother Pharmacol 32:78-81
7. Dorr RT (1991) Chemoprotectants for cancer chemotherapy. Semin Oncol 18 [Suppl 2]:48-58
8. Canadian Task Force on the Periodic Health Examination (1979) The periodic health examination. Can Med Assoc J 121:1193-1254
9. Benjamin RS, Legha SS, Shreyaskumar RP, et al (1993) Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. Cancer Chemother Pharmacol 31 [Suppl 2]:S174-179
10. Scheulen ME, Niederle N, Bremer K, et al (1983) Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients. Cancer Treat Rev 10 [Suppl A]:93-101
11. Scheef W, Klein HO, Brock N, et al (1979) Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results. Cancer Treat Rep 63:501-505
12. Hsieh RK, Chang AY, Boros L, et al (1994) Phase II study of ifosfamide, carboplatin, and etoposide in patients with advanced non-small cell lung cancer. Am J Clin Oncol 17:509-513
13. Miller VA, Rigas JR, Pisters KMW, et al (1995) Ifosfamide plus high-dose cisplatin in patients with non-small cell lung cancer previously treated with chemotherapy. Am J Clin Oncol 18:303-306
14. Dirix LY, van Meerbeeck J, Schrijvers D, et al (1994) A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann Oncol 5:653-655
15. Pizzocaro G, Salvioni R, Piva L, et al (1994) Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long-term results. Ann Oncol 3:211-216
16. Millward MJ, Harris AL, Cantwell BM (1990) Phase II study of doxorubicin plus ifosfamide/mesna in patients with advanced breast cancer. Cancer 65:2421-2425
17. Zidar BL, Metch B, Balcerzak SP, et al (1992) A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study. Cancer 70:2547-2551
18. Rosen G, Forscher C, Lowenbraun S, et al (1994) Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 73:2506-2511
19. Sutton GP, Blessing JA, Homesley HD, et al (1994) Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncologic Group study. Cancer 73:1453-1455
20. Skubitz KM, Hamdan H, Thompson RC (1993) Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. Cancer 72:2963-2969
21. Graziano SL, Herndon JE, Richards F II, et al (1993) A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study. Cancer 72:62-68
22. Currie DC, Miles DW, Drake JS, et al (1990) Mitomycin, ifosfamide, and cisplatin in non-small cell lung cancer. Cancer Chemother Pharmacol 25:380-381
23. Cervellino JC, Araujo CE, Pirisi C, et al (1990) Ifosfamide and mesna at high dose for the treatment of cancer of the cervix: a GETLAC study. Cancer Chemother Pharmacol 26 [Suppl]:S1-3
24. Barton C, Buxton EJ, Blackledge G, et al (1990) A phase II study of ifosfamide in endometrial cancer. Cancer Chemother Pharmacol 26 [Suppl]:S4-6
25. Blackledge G, Buxton EJ, Mould JJ, et al (1990) Phase II studies of ifosfamide alone and in combination in cancer of the cervix. Cancer Chemother Pharmacol 26 [Suppl]:S12-16
26. Green JA, Smith K (1990) Dose-intensity of carboplatin in combination with cyclophosphamide or ifosfamide. Cancer Chemother Pharmacol 26 [Suppl]:S22-25
27. Lara PC, Garcia-Pucle JL, Pedraza V (1990) Cisplatin-ifosfamide as neoadjuvant chemotherapy in stage IIIB cervical uterine squamous-cell cancer. Cancer Chemother Pharmacol 26 [Suppl]:S36-38
28. Nishida T, Nagasue N, Yakushiji M (1990) Treatment of gynecological malignancies with a combination of cisplatin, adriamycin and ifosfamide. Cancer Chemother Pharmacol 26 [Suppl]:S39-42
29. Trope C, Kaern J, Vergote I, et al (1990) A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas. Cancer Chemother Pharmacol 26 [Suppl]:S45-47
30. Willemse PHB, v.d. Burs MEL, v.d. Gaast A, et al (1990) Ifosfamide as a 24-h infusion with mesna in patients with recurrent ovarian cancer preliminary results. Cancer Chemother Pharmacol 26 [Suppl]:S51-54
31. Sutton GP, Blessing JA, Photopoulos G, et al (1990) Early phase II GOG experiences with ifosfamide/mesna in gynecologic malignancies. Cancer Chemother Pharmacol 26 [Suppl]:S55-58
32. Tobias J, Buxton EJ, Blackledge G, et al (1990) Neoadjuvant bleomycin, ifosfamide and cisplatin in cervical cancer. Cancer Chemother Pharmacol 26 [Suppl]:S59-62
33. 2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer. Cancer Chemother Pharmacol 26 [Suppl]:S63-65
34. Ghavamzadeh A (1990) Treatment of metastatic breast cancer with the combination of ifosfamide, epirubicin and 5-fluorouracil. Cancer Chemother Pharmacol 26 [Suppl]:S66-68
35. Lange OF, Scheef W, Haase KD, et al (1990) Palliative chemo-radiotherapy with d1-5 ifosfamide and epirubicin as first-line treatment for high-risk metastatic breast cancer. Results of a prospective multicentre trial. Cancer Chemother Pharmacol 26 [Suppl]:S74-77
36. Bellmunt J, Morales S, Navarro M, et al (1990) Ifosfamide and mitoxantrone in advanced breast cancer - previously treated with anthracyclines. Cancer Chemother Pharmacol 26 [Suppl]:S81-84
37. Gad-El-Mawla N, Hamza MR, Zikri ZK, et al (1990) Ifosfamide, methotrexate, and 5-fluorouracil: effective combination in resistant breast cancer. Cancer Chemother Pharmacol 26 [Suppl]:S85-86
38. Manegold C, Worst P, Bickel J, et al (1990) Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer. Cancer Chemother Pharmacol 26 [Suppl]:S91-92
39. Sanchiz F, Milla A (1990) High-dose ifosfamide and mesna in advanced breast cancer. A phase II study. Cancer Chemother Pharmacol 26 [Suppl]:S91-92
40. Langenbuch T, Mross K, Jonat W, et al (1990) A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer. Cancer Chemother Pharmacol 26 [Suppl]:S93-96
41. Wiklund TA, Blomquist CP, Virolainen M, et al (1992) Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 30:100-104
42. Martin M, Diaz-Rubio E, Gonzalez Larriba JL, et al (1993) Ifosfamide in advanced epidermoid head and neck cancer. Cancer Chemother Pharmacol 31:340-342
43. Stuart Harris R, Dalley D, Bell DR, et al (1993) Ifosfamide combination regimens for soft tissue sarcoma. Cancer Chemother Pharmacol 31 [Suppl 2]:S185-188
44. Weh HJ, Agarwal K, Zornig C, et al (1993) Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide. Cancer Chemother Pharmacol 31 [Suppl 2]:S189-193
45. Hayat M, Ostronoff M, Gilles E, et al (1990) Salvage therapy with methyl-gag, high-dose Ara C, M-Amsa, and ifosfamide (MAMI) for recurrent or refractory lymphoma. Cancer Invest 8:1-5
46. Turrill M, Spicer DV, Kelley AS, et al (1995) Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma. Cancer Invest 13:160-164
47. Schutte J, Mouriden HT, Stewart W, et al (1990) Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 26:558-561
48. Pujol JL, Rossi JF, LeChevalier T, et al (1990) Pilot study of neoadjuvant ifosfamide, cisplatin, and etoposide in locally advanced non-small cell lung cancer. Eur J Cancer 26:798-780
49. Postmus PE, Smit EF, Kirkpatrick A, et al (1994) Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 29:204-207
50. Sutton GP, Blessing JA, Disaia PJ, et al (1993) Phase II study of ifosfamide and mesna in non-squamous carcinoma of the cervix: a Gynecologic Oncologic Group study. Gynecol Oncol 49:48-50
51. Sutton GP, Blessing JA, Homesley HD, et al (1994) A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncologic Group study. Gynecol Oncol 53:24-26
52. Markman M, Hakes T, Reichman B, et al (1992) Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 10:243-248
53. Antman K, Crowley J, Balcerzak SP, et al (1993) An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11:1276-1285
54. Cullen MH (1993) Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer. Oncology 50 [Suppl 1]:31-34
55. Palackdharry CS, Krigel RL (1994) Dose-intensive ifosfamide/carboplatin/etoposide plus granulocyte-macrophage colony-stimulating factor for non-small cell lung cancer. Semin Oncol 21 (3) [Suppl 4]:6-11
56. Baldini E, Tibaldi C, Chella A, et al (1994) Combination chemotherapy with vinorelbine, ifosfamide, and cisplatin: a phase II study in stage IIIB-IV non-small cell lung cancer. Semin Oncol 21 (3) [Suppl 4]:12-15
57. Wolf M, Hans K, Hassler R, et al (1994) Radiotherapy alone versus chemotherapy with ifosfamide/vindesine followed by radiotherapy in unresectable locally advanced non-small cell lung cancer. Semin Oncol 21 (3) [Suppl 4]:42-47
58. Shirinian M, Lee JS, Dhingra HH, et al (1992) Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer. Semin Oncol 19 (1) [Suppl 1]:49-53
59. Shepherd FA, Evans WK, Goss PE, et al (1992) Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer. Semin Oncol 19 (1) [Suppl 1]:54-58
60. Fukuoka M, Negoro S, Masuda N, et al (1991) Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. J Cancer Res Clin Oncol 117:473-478
61. Sakurai M, Saijo N, Shinkai T, et al (1986) The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial. Jpn J Clin Oncol 16:153-156
62. Bryant BM, Jarman M, Ford JT, et al (1980) Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet 8196:657-659
63. Dupont WD, Plummer BS Jr (1990) Power and sample size calculations. A review and computer program. Control Clin Trials 11:116-128
64. Kurowski V, Wagner T (1997) Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy. Cancer Chemother Pharmacol 39:431-439
65. Katz A, Epelman S, Anelli A, et al (1995) A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration. J Cancer Res Clin Oncol 121:128-131
66. Holoye PY, Glisson BS, Lee JS, et al (1990) Ifosfamide with mesna uroprotection in the management of lung cancer. Am J Clin Oncol 13:148-155
67. Goren MP (1996) Oral administration of mesna with ifosfamide. Semin Oncol 23 (3) [Suppl 6]:91-96
68. Araujo CE, Tessler J (1983) Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer. Eur J Cancer Clin Oncol 19:195-201
69. Haselberger MB, Schwinghammer TL (1995) Efficacy of mesna for prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy. Ann Pharmacol 29:919-921
70. Hows JM, Mehta A, Ward L, et al (1984) Comparison of mesna with forced diuresis to prevent cyclophosphamide induced hemorrhagic cystitis in marrow transplantation: a prospective randomized study. Br J Cancer 50:753-756
71. Shepherd JD, Pringle LE, Barnett MJ, et al (1991) Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 9:2016-2020
72. Vose JM, Reed EC, Pippert GC, et al (1993) Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial. J Clin Oncol 11:1306-1310
73. Brock NT, Pohl J, Stekar J, et al (1982) Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention (profile of action of sodium 2-mercaptoethane sulphonate). Eur J Cancer Clin Oncol 18:1377-1387
74. Bernacki RJ, Bansal SK, Gurtoo HL (1987) Combination of mesna with cyclophosphamide or Adriamycin in the treatment of mice with tumors. Cancer Res 47:799-802
75. Markman M, Kennedy A, Webster K, et al (1996) Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis. Semin Oncol 23 [Suppl 6]:97-98